Abstracts Archive - Page 2333 of 2425 - ACR Meeting Abstracts

Abstract Number: 1355 • 2012 ACR/ARHP Annual Meeting
Hand Bone Loss Is Arrested in Early Psoriatic Arthritis but Not in Rheumatoid Arthritis Following Anti-Rheumatic Treatment Assessed by Digital X-Ray Radiogrammetry
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Martina Cooney⁴, Eric J. Heffernan⁵ and Oliver M. FitzGerald¹, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Dublin Academic Medical Center, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵Radiology, Department of Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Periarticular bone loss is an early feature of both psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Digital X-ray radiogrammetry (DXR) is a sensitive method…
Abstract Number: 1316 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Roy Fleischmann¹, Ronald F. van Vollenhoven², Jiri Vencovsky³, Rieke Alten⁴, Owen Davies⁵, Christian Stach⁶, Marc de Longueville⁷, Brenda Van Lunen⁸ and Ernest Choy⁹, ¹University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ²Karolinska Institute, Stockholm, Sweden, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Certolizumab pegol (CZP) has been shown to be efficacious and have an acceptable safety profile when administered every 4 weeks (Q4W) as monotherapy (FAST4WARD,…
Abstract Number: 1317 • 2012 ACR/ARHP Annual Meeting
One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis
Janet E. Pope¹, Boulos Haraoui², J. Carter Thorne³, Melanie Poulin-Costello⁴, Andrew Vieira⁵ and Edward Keystone⁶, ¹Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ²Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Combination therapy with a biologic and methotrexate (MTX) usually yields better outcomes than biologic monotherapy in rheumatoid arthritis (RA).1,2,3 However, patients may be intolerant…
Abstract Number: 1318 • 2012 ACR/ARHP Annual Meeting
Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Vibeke Strand¹, Oana Purcaru², Ronald F. van Vollenhoven³, Ernest Choy⁴ and Roy Fleischmann⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²UCB Pharma, Brussels, Belgium, ³Karolinska Institute, Stockholm, Sweden, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Southwestern Medical Center at Dallas, University of Texas, Dallas, TX
Background/Purpose: Certolizumab pegol (CZP) monotherapy administered every 4 weeks (Q4W) for rheumatoid arthritis (RA) has been shown to be associated with rapid and sustainable improvements…
Abstract Number: 1319 • 2012 ACR/ARHP Annual Meeting
Certolizumab Pegol Plus Methotrexate Is Similarly Effective in Active Rheumatoid Arthritis Secondary Non-Responders to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib Trial
Daniel Furst¹, Saeed A. Shaikh², Maria W. Greenwald³, Michael H. Schiff⁴, Barbara Bennett⁵, Owen Davies⁶, Fabienne Staelens⁷, Will Koetse⁸ and Philippe Bertin⁹, ¹David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ²Medicine, McMaster University, St Catharines, ON, Canada, ³Desert Medical Advances, Palm Desert, CA, ⁴Rheumatology Division, University of Colorado, Denver, CO, ⁵BABennett Consulting, LLC, Marietta, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Rtp, NC, ⁹Service De Rhumatologie, Dupuytren Hospital, Limoges, France
Background/Purpose: Certolizumab pegol (CZP) has demonstrated efficacy in patients (pts) with prior TNF inhibitor exposure.1 In the Doseflex trial two maintenance dosing regimens of CZP…
Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese¹, Roy Fleischmann², Martine Jasson³, Allen R. Radin⁴, Jennifer Hamilton⁵ and Tom W.J. Huizinga⁶, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…
Abstract Number: 1321 • 2012 ACR/ARHP Annual Meeting
C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis
Ernst R. Dow¹, Poulabi Banerjee², Michelle A. Penny¹, Eric P. Nantz², Sergey Stepaniants³, Anne Ho³, Wendy J. Komocsar², Pierre-Yves Berclaz² and Robert W. Hoffman¹, ¹Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, IN, ³Covance Genomics Laboratory LLC, Seattle, WA
Background/Purpose: Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their clinical response to treatment. Despite considerable research, no…
Abstract Number: 1322 • 2012 ACR/ARHP Annual Meeting
Coadministration of ASP015K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis
Tong Zhu¹, Kazuo Oda², Udaya Valluri¹, Bogie Moore¹, Ying Cao¹, Vishala Chindalore³ and Bola Akinlade⁴, ¹Astellas Pharma Global Development, Inc., Northbrook, IL, ²Drug Metabolism Research Labs. Drug Discovery Research, Astellas Pharma Inc., Osaka, Japan, ³Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL, ⁴Immunology Development, Astellas Pharma Global Development, Inc., Northbrook, IL
Background/Purpose: ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid arthritis (RA) and other autoimmune diseases.…
Abstract Number: 1323 • 2012 ACR/ARHP Annual Meeting
Effects of Dose Escalation of Tocilizumab in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: Sub-Analysis of a 24-Week Study in a United States Population
M. E. Weinblatt¹, Herbert S. B. Baraf², Ara H. Dikranian³, Andrew M. Anisfeld⁴, Jenny Devenport⁴ and Sheldon Cooper⁵, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³San Diego Arthritis Medical Clinic, San Diego, CA, ⁴Genentech, South San Francisco, CA, ⁵Rheum & Clinical Imm Unit, Univ Vermont College of Med, Burlington, VT
Background/Purpose: In the US, the recommended starting dose of Tocilizumab (TCZ) is 4 mg/kg (q4w) with an increase to 8 mg/kg (q4w) based on clinical…
Abstract Number: 1324 • 2012 ACR/ARHP Annual Meeting
Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 104 Results of Clinical, Radiographic and Safety Assessments
Tsutomu Takeuchi¹, Masayoshi Harigai², Yoshiya Tanaka³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Kazuhiko Yamamoto⁶, Minoru Kanazawa⁷, Yoshinori Murakami⁸, Toru Yoshinari⁹, Daniel Baker¹⁰, Nobuyuki Miyasaka¹¹ and Takao Koike¹², ¹Keio University School of Medicine, Tokyo, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁶Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Director of Respiratory Center Professor of Respiratory, Medicine Saitama Medical University, Moroyama, Iruma-Gun, Saimata, Japan, ⁸Medical writing, Janssen Pharmaceutical KK, Tokyo, Japan, ⁹2-6-18, Kitahama, Chuo-ku, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, ¹⁰Janssen Research & Development, LLC., Spring House, PA, ¹¹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹²Sapporo medical center NTT EC, Sapporo, Japan
Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks as Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy:…
Abstract Number: 1325 • 2012 ACR/ARHP Annual Meeting
Prevention of Joint Destruction in Patients with High Disease Activity or High C-Reactive Protein
Yoshiya Tanaka¹, Masayoshi Harigai², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Kazuhiko Yamamoto⁶, Yutaka Ishii⁷, Daniel Baker⁸, Nobuyuki Miyasaka⁹ and Takao Koike¹⁰, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁶Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ⁷Medical Affaires, Janssen Pharmaceutical K.K, Tokyo, Japan, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁰Sapporo medical center NTT EC, Sapporo, Japan
Prevention of Joint Destruction in Patients with High Disease Activity or High C-reactive proteinBackground/Purpose: In Japan, 2 doses (50mg and 100mg) of golimumab (GLM) were…
Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Lillian J. Barra¹, Andrew Ha², Louise Sun³, Catarina Fonseca⁴ and Janet E. Pope⁵, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²The University of Toronto, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Universidade de Lisboa, Lisbon, Portugal, ⁵Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…
Abstract Number: 1327 • 2012 ACR/ARHP Annual Meeting
Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea
Mi-Il Kang, Yoon Kang, Hee-Jin Park, Hyang-Sun Lee, Sang-Won Lee, Yong-Beom Park and Soo-Kon Lee, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: The previous studies reported that intensive treatment-strategies, including biological agents and glucocorticoids, can improve the severity of early rheumatoid arthritis. However, there was no…
Abstract Number: 1328 • 2012 ACR/ARHP Annual Meeting
The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Yoshinobu Koyama¹, Kazunori Hase², Daisuke Hidaka², Shuji Nagano³, Toshiyuki Ota³ and Ayumi Uchino², ¹Division of Rheumatology, Okayama Red Cross General Hospital, Okayama, Japan, ²Iizuka Hospital, Iizuka, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose: Although data are conflicting with regard to the clinical utility of MTX polyglutamates (PGs) measurements as a predictor of the efficacy or toxicity in…
Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Anne C. Bay-Jensen¹, Inger Byrjalsen², Andrew Kenwright³, Thierry Sornasse⁴, Claus Christiansen⁵ and Morten Asser Karsdal⁶, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³Roche, Welwyn Garden City, United Kingdom, ⁴Genentech, South San Francisco, ⁵CCBR, Ballerup, Denmark, ⁶Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].